<DOC>
	<DOCNO>NCT02427126</DOCNO>
	<brief_summary>Multicentre ( national , Germany ) , randomize ( 2x2 factorial ) , open , parallel group , active control , efficacy study ( phase III )</brief_summary>
	<brief_title>Apixaban Treatment Embolic Stroke Undetermined Source</brief_title>
	<detailed_description>Based previous data , ATTICUS design multicentre , national , parallel groupactive control , phase III randomize ( 2x2 factorial ) , clinical trial demonstrate superiority apixaban current standard treatment ( acetylsalicylic acid ) longterm treatment ESUS . ATTICUS follow dynamic treatment protocol implement conversion acetylsalicylic acid arm apixaban arm case detection relevant episodes AF course study . ! ATTICUS design test superiority acetylsalicylic acid reduce new ischemic lesion detect FLAIR/DWI MRI .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Salicylic Acid</mesh_term>
	<criteria>Inclusion criterion Must ≥ 18 year time signing informed consent . ESUS must define accord follow criterion : Stroke detect CT MRI lacunar Absence extracranial intracranial atherosclerosis cause ≥50 % luminal stenosis artery supply area ischaemia No majorrisk cardioembolic source embolism No specific cause stroke identify * At least one follow nonmajor suggestive risk factor cardiac embolism : LA size &gt; 45mm ( parasternal axis ) spontaneous echo contrast LAA LAA flow velocity &lt; =0.2m/s atrial high rate episode CHA2DS2Vasc score &gt; =4 persistent foramen ovale Understand voluntarily sign informed consent document Women childbearing potential ( WOCBP ) must use adequate method contraception . History hypersensitivity investigational medicinal product Participation clinical trial observation period compete trial . Arteria cerebri medium stroke affect &gt; 30 % c r r e p n n g territory Diagnosis haemorrhage pathology , Clear indication anticoagulation Inability control follow risk factor Hemorrhagic Transformation fresh cerebral Infarction ( HTI ) index hospital stay : presence HTI time anticoagulation , blood pressure &gt; 140 mmHg systolic , abnormal blood glucose Clear indication dual antiplatelet therapy Clear stroke/nonstrokeindication concomitant longterm therapy antiplatelets ( e.g . acetylsalicylic acid ( ASA ) , Clopidogrel , Prasugrel ) nonsteroidal antiinflammatory drug ( NSAID ) . Concomitant systemic therapy strong inhibitor cytochrome P450 3A4 ( CYP3A4 ) Pglycoprotein ( Pgp ) , i.e . azoleantimycotics human immunodeficiency virus ( HIV ) protease inhibitor . Contraindication investigational medication Planned likely therapy fibrinolytic agent within 48 hour first study medication History intracranial , intraocular , spinal , retroperitoneal atraumatic intraarticular bleed Gastrointestinal bleed major surgery within 3 month Planned likely revascularization ( angioplasty vascular surgery ) within next 3 month TIA minor stroke induce angiography surgery Severe noncardiovascular comorbidity life expectancy &lt; 3 month Severe renal failure , define Glomerular Filtration Rate ( GFR ) &lt; 15ml/min Severe hepatic insufficiency ( ChildPugh score B C ) , Active liver disease , Contraindications performance MRI ( pacemaker/ICD ) , previous implantation nonMRI capable protheses Patients consider unreliable investigator , life expectancy less expected duration trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>